Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.

Article Details

Citation

Owens MJ, Morgan WN, Plott SJ, Nemeroff CB

Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.

J Pharmacol Exp Ther. 1997 Dec;283(3):1305-22.

PubMed ID
9400006 [ View in PubMed
]
Abstract

Several new antidepressants that inhibit the serotonin (SERT) and norepinephrine transporters (NET) have been introduced into clinical practice the past several years. This report focuses on the further pharmacologic characterization of nefazodone and its metabolites within the serotonergic and noradrenergic systems, in comparison with other antidepressants. By use of radioligand binding assays, we measured the affinity (Ki) of 13 antidepressants and 6 metabolites for the rat and human SERT and NET. The Ki values for eight of the antidepressants and three metabolites were also determined for the rat 5-HT1A, 5-HT2A and muscarinic cholinergic receptors, the guinea pig histamine1 receptor and the human alpha-1 and alpha-2 receptors. These data are useful for predicting side effect profiles and the potential for pharmacodynamic drug-drug interactions of antidepressants. Of particular interest were the findings that paroxetine, generally thought of as a selective SERT antagonist, possesses moderately high affinity for the NET and that venlafaxine, which has been described as a "dual uptake inhibitor", possesses weak affinity for the NET. We observed significant correlations in SERT (r = 0.965) or NET (r = 0.983) affinity between rat and human transporters. Significant correlations were also observed between muscarinic cholinergic and NET affinity. There are several significant correlations between affinities for the 5-HT1A, 5-HT2A, histamine1, alpha-1 and alpha-2 receptors. These novel findings, not widely described previously, suggest that many of the individual drugs studied in these experiments possess some structural characteristic that determines affinity for several G protein-coupled, but not muscarinic, receptors.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
AmitriptylineAlpha-2A adrenergic receptorKi (nM)114N/AN/ADetails
AmitriptylineSodium-dependent noradrenaline transporterKi (nM)19N/AN/ADetails
AmitriptylineSodium-dependent noradrenaline transporterKi (nM)102N/AN/ADetails
AmitriptylineSodium-dependent serotonin transporterKi (nM)2.8N/AN/ADetails
CitalopramSodium-dependent serotonin transporterKi (nM)8.9N/AN/ADetails
CitalopramSodium-dependent serotonin transporterKi (nM)1.5N/AN/ADetails
ClomipramineSodium-dependent serotonin transporterKi (nM)0.05N/AN/ADetails
DesipramineSodium-dependent noradrenaline transporterKi (nM)0.63N/AN/ADetails
DesipramineSodium-dependent noradrenaline transporterKi (nM)3.5N/AN/ADetails
DesipramineSodium-dependent serotonin transporterKi (nM)163N/AN/ADetails
DesipramineSodium-dependent serotonin transporterKi (nM)22N/AN/ADetails
DesvenlafaxineSodium-dependent noradrenaline transporterKi (nM)2753N/AN/ADetails
DesvenlafaxineSodium-dependent noradrenaline transporterKi (nM)3152N/AN/ADetails
DesvenlafaxineSodium-dependent serotonin transporterKi (nM)115N/AN/ADetails
DesvenlafaxineSodium-dependent serotonin transporterKi (nM)7.7N/AN/ADetails
FluoxetineSodium-dependent serotonin transporterKi (nM)20N/AN/ADetails
FluoxetineSodium-dependent serotonin transporterKi (nM)0.9N/AN/ADetails
FluvoxamineSodium-dependent serotonin transporterKi (nM)14N/AN/ADetails
FluvoxamineSodium-dependent serotonin transporterKi (nM)1.6N/AN/ADetails
ImipramineSodium-dependent noradrenaline transporterKi (nM)20N/AN/ADetails
ImipramineSodium-dependent noradrenaline transporterKi (nM)142N/AN/ADetails
ImipramineSodium-dependent serotonin transporterKi (nM)20N/AN/ADetails
ImipramineSodium-dependent serotonin transporterKi (nM)1.3N/AN/ADetails
MazindolSodium-dependent noradrenaline transporterKi (nM)0.46N/AN/ADetails
MazindolSodium-dependent noradrenaline transporterKi (nM)1.93N/AN/ADetails
NefazodoneAlpha-2A adrenergic receptorKi (nM)84N/AN/ADetails
NefazodoneSodium-dependent noradrenaline transporterKi (nM)618N/AN/ADetails
NefazodoneSodium-dependent noradrenaline transporterKi (nM)713N/AN/ADetails
NefazodoneSodium-dependent serotonin transporterKi (nM)549N/AN/ADetails
NefazodoneSodium-dependent serotonin transporterKi (nM)459N/AN/ADetails
NortriptylineSodium-dependent noradrenaline transporterKi (nM)1.8N/AN/ADetails
NortriptylineSodium-dependent noradrenaline transporterKi (nM)21N/AN/ADetails
NortriptylineSodium-dependent serotonin transporterKi (nM)279N/AN/ADetails
NortriptylineSodium-dependent serotonin transporterKi (nM)15N/AN/ADetails
ParoxetineSodium-dependent noradrenaline transporterKi (nM)85N/AN/ADetails
ParoxetineSodium-dependent noradrenaline transporterKi (nM)328N/AN/ADetails
ParoxetineSodium-dependent serotonin transporterKi (nM)0.83N/AN/ADetails
ParoxetineSodium-dependent serotonin transporterKi (nM)0.06N/AN/ADetails
TrazodoneAlpha-2A adrenergic receptorKi (nM)106N/AN/ADetails
TrazodoneSodium-dependent serotonin transporterKi (nM)690N/AN/ADetails
TrazodoneSodium-dependent serotonin transporterKi (nM)252N/AN/ADetails
VenlafaxineSodium-dependent noradrenaline transporterKi (nM)2269N/AN/ADetails
VenlafaxineSodium-dependent noradrenaline transporterKi (nM)1644N/AN/ADetails
VenlafaxineSodium-dependent serotonin transporterKi (nM)102N/AN/ADetails
VenlafaxineSodium-dependent serotonin transporterKi (nM)7.5N/AN/ADetails
YohimbineAlpha-2A adrenergic receptorKi (nM)0.71N/AN/ADetails